Enterprise League logo
MeCo Diagnostics Logo

MeCo Diagnostics

San Diego, United States (US) · Science and Engineering

We built this page from public sources. What we do with your data

Do you work at MeCo Diagnostics?

Claim this profile to manage your company.

Verified by Enterprise League

Data quality

Complete · Accuracy

MeCo Diagnostics is a Science and Engineering company based in San Diego, United States (US), founded in 2022, with 2-10 employees. MeCo Diagnostics's profile is verified on Enterprise League.

Overview

Venture-backed startup developing first-in-class predictive biomarker tests to harness low-toxicity, repurposed or repositioned antifibrotic drugs for cancer metastasis prevention. MeCo Diagnostics traces its origins to the oldest observation in cancer biology: tumors often grow stiffer than surrounding tissue, leading to a palpable lump, which is the most common indicator of disease. Not all cancer cells are responsive to increased stiffness of their microenvironment, but those that are become “mechanically conditioned,” akin to deadly, microscopic wind-up machines that are destined to wreak havoc as they spread throughout the body. Mechanical conditioning as a problem dictates mechanical deconditioning as a solution; fortunately, there are FDA-approved antifibrotic drugs which can be repurposed for this need. This serendipity has empowered us to develop a commercially viable, biomarker-enabled drug repurposing approach that synergizes with conventional neoadjuvant treatments. Our lead asset, for breast cancer, has been rigorously validated in 4 independent clinical studies comprised of over 4000 patients total, in partnership with oncologists at Cleveland Clinic, the University of Arizona, and the Spanish National Cancer Research Center. Ultimately, we aim to reduce breast and prostate cancer burden in patients before surgery, leading to higher rates of lifelong remission. Since we are leveraging generic-emergent drugs, the cost of targeted antifibrotic therapy may soon be >10X cheaper than any other targeted therapy for breast or prostate cancer in development. Since the value of predictive biomarker tests is inversely proportional to the cost of their associated therapies, harnessing generics benefits all stakeholders: patients, payers, and our shareholders. For more information on our team, our research, or our current fundraising round, please reach out.

Most teams do this before shortlisting


Contact Details

adam@mecodiagnostics.com

San Diego, United States (US)

Founded

2022

Company Type

Private Limited Company

Employees

2-10

Categories

Awards

• 2026 OpenSee all

Companies teams usually look at after MeCo Diagnostics

Comparing a few options usually leads to better decisions






  • Save companies to compare later. Useful when sharing options with your team

This is how your company profile looks to others.